Media

페이지 정보

본문

Professor Seong-Woon Yu's Team Presents Poster at the American Society of Microbiology:

“GV1001 Enhances Microglial Migration and Induces Phagocytosis”

Research findings reveal that when GV1001 was administered to mice with moderate Alzheimer’s disease, amyloid beta levels were reduced to normal, healthy levels.

The study demonstrated that GV1001 promotes the movement of microglia—brain cells that act as cleaners—and induces phagocytosis, facilitating the removal of amyloid beta, which is known to be harmful to the brain.

On the 30th, GemVax & KAEL Co., Ltd. (hereinafter GemVax, 082270) announced that Professor Seong-Woon Yu's team at Daegu Gyeongbuk Institute of Science and Technology (DGIST) presented a poster detailing the results of their study on GV1001's mechanism for amyloid beta clearance at the "ReThink Neuroimmunology Symposium 2024," held at the University of Washington on the 26th (local time).

The study found that GV1001 enhances the clearance of amyloid beta by promoting microglial migration toward amyloid plaques and inducing phagocytosis. Notably, the research team observed that this microglial activity activates a signaling pathway (mTORC2) that regulates proteins involved in cell survival and the cell cycle, further facilitating the removal of amyloid plaques.

In conclusion, the study confirmed that GV1001 not only reduces amyloid plaques in the brain but also delays memory decline and neuronal damage in an Alzheimer's disease mouse model.

Professor Yu commented, “GV1001 has the potential to be a treatment that alleviates Alzheimer's symptoms while also slowing or halting disease progression.” He added, “These findings provide new hope for Alzheimer’s treatment and represent a significant breakthrough in dementia research. We plan to continue investigating GV1001 as a treatment for Alzheimer's and further validate its specific mechanisms.”

A GemVax official remarked, “This study reaffirms that GV1001 is a drug with the potential for fundamentally treating Alzheimer’s disease. As GV1001 expands its indications to include other neurodegenerative diseases, such as progressive supranuclear palsy, we anticipate meaningful results from various studies, including mechanism investigations and clinical trials.”

The "ReThink Neuroimmunology Symposium" took place from the 25th to the 27th, gathering experts from research institutes and the pharmaceutical industry to share a wide range of research findings in the field of neuroimmunology.

댓글목록

등록된 댓글이 없습니다.